Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has ...

Double-digit compound annual revenue growth over the past 18 years 18 July 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy ...

The global birch allergy market is experiencing robust growth due to increasing cases of allergic rhinitis from birch pollen and advancements in treatments like immunotherapy. Rising awareness and ...

LONDON - Allergy Therapeutics plc (AIM: AGY), a commercial biotechnology company specializing in allergy vaccines, has granted share options to select members of its management team, including ...

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, today announces positive results from its Pollinex Quattro Grass Phase III study ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks The latest announcement is out from Allergy Therapeutics ( (GB:AGY)). Allergy Therapeutics has announced a ...

New York, United States , July 03, 2024 (GLOBE NEWSWIRE) -- The Global Allergy Therapeutics Market Size is to Grow from USD 23.1 Billion in 2023 to USD 42.5 Billion by 2033, at a Compound Annual ...

Allergy Therapeutics is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold strategy centred on innovation.

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

According to Market.us, the anticipated value of the Global Allergy Diagnostics and Therapeutics Market is projected to reach approximately USD 79.6 Billion by 2033. This significant growth is ...

2005 Engineering and Wharton graduate Meenal Lele founded the biotechnology company Hanimune Therapeutics, which develops food allergy preventative products (Photo courtesy of Meenal Lele). 2005 ...